These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31284855)

  • 1. Molecular Docking Supplements an In vitro Determination of the Leading CYP Isoform for Arylpiperazine Derivatives.
    Ulenberg S; Bączek T; Zieliñska J; Belka M; Król M; Herold F
    Comb Chem High Throughput Screen; 2019; 22(6):370-378. PubMed ID: 31284855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme.
    Tie Y; McPhail B; Hong H; Pearce BA; Schnackenberg LK; Ge W; Buzatu DA; Wilkes JG; Fuscoe JC; Tong W; Fowler BA; Beger RD; Demchuk E
    Molecules; 2012 Mar; 17(3):3407-60. PubMed ID: 22421793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Site of Metabolism (SOM) Prediction of Ligand for CYP3A4 Enzyme: Comparison of Glide XP and Induced Fit Docking (IFD).
    Lokwani DK; Sarkate AP; Karnik KS; Nikalje APG; Seijas JA
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32244772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation.
    Niwa T; Yasumura M; Murayama N; Yamazaki H
    Drug Metab Lett; 2014; 8(1):43-50. PubMed ID: 24484539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and in silico prediction of metabolites of the model compound, tebufenozide by human CYP3A4 and CYP2C19.
    Shirotani N; Togawa M; Ikushiro S; Sakaki T; Harada T; Miyagawa H; Matsui M; Nagahori H; Mikata K; Nishioka K; Hirai N; Akamatsu M
    Bioorg Med Chem; 2015 Oct; 23(20):6594-601. PubMed ID: 26404412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and in silico prediction of metabolites of tebufenozide derivatives by major human cytochrome P450 isoforms.
    Edamatsu H; Yagawa M; Ikushiro S; Sakaki T; Nakagawa Y; Miyagawa H; Akamatsu M
    Bioorg Med Chem; 2020 May; 28(9):115429. PubMed ID: 32201191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer.
    Subhani S; Jamil K
    Biomed Pharmacother; 2015 Jul; 73():65-74. PubMed ID: 26211584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
    Saba N; Seal A
    J Mol Model; 2018 Mar; 24(4):82. PubMed ID: 29502215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of In Vitro and Predictive In Silico Models to Study the Inhibition of Cytochrome P4503A by Stilbenes.
    Basheer L; Schultz K; Fichman M; Kerem Z
    PLoS One; 2015; 10(10):e0141061. PubMed ID: 26485399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XenoSite: accurately predicting CYP-mediated sites of metabolism with neural networks.
    Zaretzki J; Matlock M; Swamidass SJ
    J Chem Inf Model; 2013 Dec; 53(12):3373-83. PubMed ID: 24224933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico and in vitro studies on interaction of novel non-imidazole histamine H
    Podlewska S; Latacz G; Łażewska D; Kieć-Kononowicz K; Handzlik J
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127147. PubMed ID: 32249114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gomisin A is a Novel Isoform-Specific Probe for the Selective Sensing of Human Cytochrome P450 3A4 in Liver Microsomes and Living Cells.
    Wu JJ; Ge GB; He YQ; Wang P; Dai ZR; Ning J; Hu LH; Yang L
    AAPS J; 2016 Jan; 18(1):134-45. PubMed ID: 26361765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Steroid Hormone Hydroxylations by and Docking to Human Cytochromes P450 3A4 and 3A5.
    Niwa T; Narita K; Okamoto A; Murayama N; Yamazaki H
    J Pharm Pharm Sci; 2019; 22(1):332-339. PubMed ID: 31339834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational dynamics of CYP3A4 demonstrate the important role of Arg212 coupled with the opening of ingress, egress and solvent channels to dehydrogenation of 4-hydroxy-tamoxifen.
    Shahrokh K; Cheatham TE; Yost GS
    Biochim Biophys Acta; 2012 Oct; 1820(10):1605-17. PubMed ID: 22677141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. beta-caryophyllene oxide and trans-nerolidol affect enzyme activity of CYP3A4 - in vitro and in silico studies.
    Špičáková A; Bazgier V; Skálová L; Otyepka M; Anzenbacher P
    Physiol Res; 2019 Nov; 68(Suppl 1):S51-S58. PubMed ID: 31755290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
    Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
    Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The computational model to predict accurately inhibitory activity for inhibitors towards CYP3A4.
    Xie Z; Zhang T; Wang JF; Chou KC; Wei DQ
    Comput Biol Med; 2010; 40(11-12):845-52. PubMed ID: 20951982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Dynamics Simulation Framework to Probe the Binding Hypothesis of CYP3A4 Inhibitors.
    Kiani YS; Ranaghan KE; Jabeen I; Mulholland AJ
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Silico Predictions of Drug - Drug Interactions Caused by CYP1A2, 2C9 and 3A4 Inhibition - a Comparative Study of Virtual Screening Performance.
    Kaserer T; Höferl M; Müller K; Elmer S; Ganzera M; Jäger W; Schuster D
    Mol Inform; 2015 Jun; 34(6-7):431-57. PubMed ID: 27490388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flavokawain A inhibits Cytochrome P450 in in vitro metabolic and inhibitory investigations.
    Niu L; Ding L; Lu C; Zuo F; Yao K; Xu S; Li W; Yang D; Xu X
    J Ethnopharmacol; 2016 Sep; 191():350-359. PubMed ID: 27318274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.